Efficacy and Safety of Guselkumab for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Dermatol Pract Concept · 2026 · PMC13211939 · PMID 42190179

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In contrast, efficacy among younger pediatric patients (6–12 years) was further reduced and did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.